Erratum: Current peptide vaccine and immunotherapy approaches against Alzheimer's disease

Abstract

In the published article cited above, there was an error at the start of paragraph five, section two, β-Amyloid peptide vaccines where ACI-24 is introduced: the company behind ACI-24 was mis-attributed. The first sentence of the paragraph originally read: ACI-24 (AC Immune, Roche and Genentech) is designed to avoid eliciting a Th-1 response to Aβ. The sentence should read: ACI-24 (AC Immune) is designed to avoid eliciting a Th-1 response to Aβ. There was also an error at the start of paragraph six, section two, β-Amyloid peptide vaccines where ABvac40 is introduced: the company behind ABvac40 was mis-attributed. The first sentence of the paragraph originally read: ABvac40 (Axon Neuroscience SE) is designed to target the C-terminus of Aβ1–40. The sentence should read: ABvac40 (Araclon Biotech) is designed to target the C-terminus of Aβ1–40. The authors apologise for any inconvenience this may have caused. DOI: 10.1002/pep2.24309